Attached files
file | filename |
---|---|
10-K/A - 10-K/A - GALECTIN THERAPEUTICS INC | d188055d10ka.htm |
EX-31.3 - EX-31.3 - GALECTIN THERAPEUTICS INC | d188055dex313.htm |
EX-31.4 - EX-31.4 - GALECTIN THERAPEUTICS INC | d188055dex314.htm |
Exhibit 10.50
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY **) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Effective Date: | April 15, 2015 | Sponsor: | Galectin Therapeutics, Inc. | |||
Protocol No: | GT-026 (Project #NASH-CX) |
Sponsor Contact: | Jack Callicutt | |||
PPD Project Manager: | ** | Bus Dev Director: | ** |
The Project Addendum by and between PPD Development, L.P., a Delaware limited partnership and successor-in-interest to PPD Development, LLC, (PPD) and Galectin Therapeutics, Inc. (Sponsor) effective as of January 10, 2015 regarding the above-referenced Protocol shall be modified as follows:
General:
| The timeline is being extended by approximately seven (7) months, where the PPD end of Involvement date has been revised from 01 July 2017 to 01 February 2018. |
| Inflationary costs associated with this timeline extension have been captured as a line item in the study budget. |
| New activities have been added in North America (NA) to capture the additional labor needed for Protocol Amendment 1. |
| New activities have been added to capture the Direct and Pass Through Costs for Central Reader Site Evaluation, Interim Monitoring, and Site Closeout Visits for Hepatic Venous Pressure Gradient (HPVG) and Liver Biopsy. |
| New activity has been added to capture the labor associated with the mapping of raw data to the Study Data Tabulation Module (SDTM). |
| The Site Country Mix has been revised as detailed below: |
Country |
Number of sites per Project Addendum |
Number of sites per Project Addendum Modification #1 | ||
** | ** | ** | ||
** | ** | ** |
| All tasks associated with **, where work has not already occurred, have been removed as the study has left the country entirely. |
Estimated costs associated with this Project Addendum Modification: | $ 218,201.92 | Direct Fees | ||||
$7,586,684.89 | Pass Through Costs | |||||
$7,804,886.80 | Total Costs |
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
Page 1 of 31
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Cumulative |
Budget NA |
Budget EMEA |
Total Budget | |||||||||
TOTAL DIRECT COSTS |
$ | 9,059,751.07 | $ | 24,941.56 | $ | 9,084,692.63 | ||||||
TOTAL PASS THROUGH COSTS |
$ | 13,293,084.54 | $ | 368,913.80 | $ | 13,661,998.34 | ||||||
TOTAL STUDY COSTS |
$ | 22,352,835.61 | $ | 393,855.36 | $ | 22,746,690.97 | ||||||
Prior |
||||||||||||
TOTAL DIRECT COSTS |
$ | 8,842,785.02 | $ | 23,705.69 | $ | 8,866,490.71 | ||||||
TOTAL PASS THROUGH COSTS |
$ | 5,738,284.26 | $ | 337,029.19 | $ | 6,075,313.45 | ||||||
TOTAL STUDY COSTS |
$ | 14,581,069.28 | $ | 360,734.88 | $ | 14,941,804.16 | ||||||
Incremental |
||||||||||||
TOTAL DIRECT COSTS |
$ | 216,966.05 | $ | 1,235.87 | $ | 218,201.92 | ||||||
TOTAL PASS THROUGH COSTS |
$ | 7,554,800.28 | $ | 31,884.61 | $ | 7,586,684.89 | ||||||
TOTAL STUDY COSTS |
$ | 7,771,766.33 | $ | 33,120.47 | $ | 7,804,886.80 |
A revised estimated study timeline is attached hereto as Exhibit A and which replaces the estimated study timeline set forth in section 1.16 of Exhibit A to the Project Addendum.
A detailed explanation of the changes to the budget is attached hereto as Exhibit B. A revised Central Labs budget is attached hereto as Exhibit C. A revised study budget is attached hereto at Exhibit D, and which replaces the budget set forth in Exhibit B to the Project Addendum.
Payment of such costs shall be made in accordance with the Revised Payment Schedule attached hereto as Exhibit E which shall replace the payment schedule set forth in Exhibit C to the Project Addendum.
All Exhibits attached hereto and incorporated herein by reference.
This Project Addendum Modification may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Each party may execute this Project Addendum Modification by facsimile transmission or in Adobe Portable Document Format (PDF) sent by electronic mail. Facsimile or PDF signatures of authorized signatories of the parties will be deemed to be original signatures, will be valid and binding, and, upon delivery, will constitute due execution of this Project Addendum Modification.
Upon execution by the parties, this Project Addendum Modification will be made a part of the Project Addendum and incorporated by reference therein. Except as expressly provided herein or in any other mutual written agreement by the parties, all terms and conditions contained in the Project Addendum shall remain in full force and effect. In the event of any conflict between the terms of this Project Addendum Modification and the Project Addendum, the terms of this Project Addendum Modification shall govern and control. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Project Addendum.
SIGNATURES FOLLOW ON NEXT PAGE
Page 2 of 31
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
ACCEPTED AND AGREED:
PPD Development, L.P. By: PPD GP, LLC Its General Partner |
Galectin Therapeutics, Inc. | |||||||
By: | /s/ Patti McNamara | By: | /s/ Peter G. Traber | |||||
Name: | Patti McNamara | Name: | Peter G. Traber | |||||
Title: | VP Finance | Title: | CEO and CMO | |||||
Date: | March 11, 2016 | Date: | March 11, 2016 |
Remainder of Page Intentionally Left Blank
Page 3 of 31
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Exhibit A
Revised Estimated Study Timeline
Activity |
As of Project Addendum |
As of Project Addendum Modification #1 | ||
Duration in Months | ||||
Pre-Study Activities |
** | ** | ||
Enrollment Period |
** | ** | ||
Treatment Period |
** | ** | ||
Close-Down Period |
** | ** | ||
Total PPD Commitment |
** | ** |
Remainder of Page Intentionally Left Blank
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
Page 4 of 31
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Exhibit B
Detailed Explanation of Change
The Detailed Explanation of Change follows this cover page
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
Page 5 of 31
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1 Cumulative Study Budget as of Project Addendum Modification #1
Department/Activity Project Management Unit Type Unit Cost NA Total Hours NA # of Units NA Budget NA Total Hours NA ft of Units NA Budget NA Total Hours NA # of Units NA Budget NA
Justification
Develop Country Budget and Payment Schedule Template ** ** ** ** ** ** ** ** ** ** ** longer projected to be achieved, due to the study leaving,
Canada.
ICF Local CustomizedReview and Approve ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the
study leaving Canada
ICF Local CustomizationReview and Approve -Amendments ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected
to be achieved, due to the study leaving Canada.
Project ManagementStart-up ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven
(7) month timeline extension.
Project ManagementEnrollment ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline
extension.
Project ManagementProtocol Amendment 1 ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the additional labor needed for Protocol
Amendment 1.
** ** ** ** ** ** ** ** ** ** **
ICF Local Customization ** **
** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Management of Translation of
Protocol, Investigator Brochure, ICF & Technical Documents ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Review of Translation of ICF ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Client Teleconferences ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Internal Team Meetings ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Site Intelligence and Activation Management ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Hepatic Venous Pressure Gradient (HVPG) Vendor Site Evaluation Visit Prep/Follow-up ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with Hepatic
Venous Pressure Gradient (HVPG) Site Evaluation Visits for Central Reader.
HVPG Vendor Site Evaluation VisitTime On Site ** ** ** ** ** ** ** ** ** ** ** New
activity added to capture labor associated with HVPG Site Evaluation Visits for Central Reader.
HVPG Vendor Site Evaluation VisitTravel ** ** ** ** ** ** **
** ** ** ** New activity added to capture labor associated with HVPG Site Evaluation Visits for Central Reader.
Subtotal ** ** ** ** ** ** ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued:
17 February 2016
**Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budget as of Project Addendum Modification #1 Cumulative
Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1
Department/Activity Unit Type Unit Cost NA Total Hours NA # of Units
NA Budget NA Total Hours NA # of Units NA Budget NA Total Hours NA # of Units NA Budget NA Justification
Clinical Management
ICF Local CustomizationAmendments ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
AmendmentsManagement of Translation of Protocol, Investigator Brochure, ICF & Technical Documents ** ** ** ** ** ** ** ** ** ** ** Activity
decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
AmendmentsReview of Translation of ICF ** ** ** ** ** ** ** ** **
** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada-
Site Initiation VisitsPrep/Admin/Follow-up ** ** **
** ** ** ** ** ** ** ** Activity i increased due to additional unit needed, as sponsor requested an additional site.
Site Initiation VisitsTime on Site ** **
** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor requested an additional site
Site Initiation VisitsTravel ** ** ** **
** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor requested an additional site
Site Management ** ** ** ** ** ** ** ** ** ** **
Activity increased due to the seven (7) month timeline extension.
Annual Investigator File Audits ** ** ** ** ** ** ** ** ** ** ** Activity increased due to
Protocol Amendment 1.
Site Closeout VisitsPrep/Admin/Follow-up ** ** ** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor
requested an additional site.
Site Closeout VisitsTime on Site ** ** ** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor
requested an additional site.
Site Closeout VisitsTravel ** ** ** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor
requested an additional site.
Unblended Investigator Meeting ** ** ** ** ** ** ** ** ** ** ** Activity decreased due to the inability to identify unblended
Clinical Research Associates (CRAs) in time to attend meeting.
CRA Team Meetings ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected
to be achieved.
Unblended CRA Team Meetings ** ** ** ** ** ** ** ** ** ** ** Activity increased due to Protocol Amendment 1.
Clinical Team Management ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Clinical ManagementProtocol Amendment 1 ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the additional labor needed for Protocol Amendment 1
HVPG Vendor Interim Monitoring VisitsPrep/Follow-Up ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with HVPG Interim Monitoring Visits (IMVs)
for Central Reader.
HVPG Vendor Interim Monitoring VisitsTime On Site ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with
HVPG IMVs for Central Reader.
HVPG Vendor Interim Monitoring VisitsTravel ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated
with HVPG IMVs for Central Reader.
PPD Pmnnrfan; and Confidential
PPD BC#:
58004-01
Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budgetas of Project Addendum Modification #1 Cumulative Study
Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1
Department/Activity Unit Type Unit Cost NA Total Hours NA # of Units NA
Budget NA Total Hours NA # of Units NA Budget NA Total Hours NA # of Units NA Budget NA Justification
HVPG Vendor Site Closeout VisitPrep/Follow-Up ** ** **
** ** ** ** ** ** ** ** New activity added to capture labor associated with HVPG Closeout Visits (COVs) for Central Reader.
HVPG Vendor Site Closeout
VisitTime On Site ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with HVPG COVs for Central Reader.
HVPG Vendor Site
Closeout VisitTravel ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with HVPG COVs for Central Reader.
Liver Biopsy Vendor
Interim Monitoring Visits -Prep/Follow-Up ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with Liver Biopsy IMVs for Central Reader.
Liver Biopsy Vendor Interim Monitoring VisitsTime On S:te ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with Liver Biopsy
IMVs for Central Reader.
Liver Biopsy Vendor Interim Monitoring VisitsTravel ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated
with Liver Biopsy IMVs for Central Reader.
Liver Biopsy Vendor Site Closeout VisitsPrep/Follow-Up ** ** ** ** ** ** ** ** ** ** ** New activity added to
capture labor associated with Liver Biopsy COVs for Central Reader.
Liver Biopsy Vendor Site Closeout VisitsTime On Site ** ** ** ** ** ** ** ** ** ** ** New
activity added to capture labor associated with Liver Biopsy COVs for Central Reader.
Liver Biopsy Vendor Site Closeout VisitsTravel ** ** ** ** ** ** ** **
** ** ** New activity added to capture labor associated with Liver Biopsy COVs for Central Reader.
Subtotal ** ** ** ** ** ** ** ** ** ** **
Identify, Select and Negotiate Contracts with Clinical Supply Vendors ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved.
Label Text Development ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved.
Label Text Translation Coordination ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Clinical Supply Forecasting ** ** ** ** ** ** ** ** ** ** ** Activity increased due to Protocol Amendment 1.
Monitor/Track Study Progress, Inventory Levels and Communication with Team/Sponsor ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline
extension.
Depot Management ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Distribution Management ** ** ** ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved.
Investigators Meeting ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the labor associated with attending the Investigators Meeting.
Global Clinical SuppliesProtocol Amendment 1 ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the additional labor needed for Protocol Amendment 1.
Subtotal ** ** ** ** ** ** ** ** ** ** **
IVRS
Investigational Product (IP) Accountability Module ** ** ** ** ** ** ** ** ** ** ** New activity added to capture labor associated with Investigational Product (IP) Accountability
Module.
Subtotal ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budget as of Project Addendum Modification #1 Cumulative
Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1
Department/Activity/ Unit Type Unit Cost NA Total Hours NA # of Units
NA Budget NA Total Hours NA # of Units NA Budget NA Total Hours NA # of Units NA Budget NA Justification
Data Management
Client Teleconferences ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Internal Team Meetings ** ** Activity increased due to the seven (7) month timeline extension.
Quality Management ** ** ** Activity increased due to the seven (7) month timeline extension.
DM Project Management ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Data ManagementProtocol Amendment 1 ** ** ** ** ** ** New activity added to capture the additional labor needed for Protocol Amendment 1.
Subtotal ** ** ** ** ** **
Pharmacovigilance
Data Safety Monitoring Board Set-up Retired and rebuilt this activity as the new activity below in order increase the labor per unit due to Protocol Amendment.
RevisedData Safety Monitoring Board Set-up ** ** ** New activity added per above in order to capture the labor associated with DSMB Set-up.
Analysis of Similar Events ** ** ** Activity decreased as unit is no longer projected to be achieved.
Development Safety Update Report (DSUR) Preparation ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Senior Medical Officer for Canada MaintenanceMonthly ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Senior Medical Officer Review of Canadian CTA ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Senior Medical Officer Review of Canadian CTA Amendment ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Data Safety Monitoring Board Face-to-Face Meeting Retired and rebuilt this activity as the new activity below in order increase the labor per unit due to Protocol
Amendment.
RevisedData Safety Monitoring Board Face to Face Meeting New activity added per above in order to capture the labor associated with Data Safety
Monitoring Board (DSMB) Face to Face meetings.
Data Safety Monitoring Board Teleconference Meeting Retired and rebuilt this activity as the new activity below in
order increase the labor per unit due to Protocol Amendment.
RevisedData Safety Monitoring Board Teleconference Meeting New activity added per above in order
to capture the labor associated with DUMB Teleconferences.
Pharmacovigilance Team Management ** ** ** ** ** Activity increased due to the seven (7) month
timeline extension.
PPD Pmnnrfan; and Confidential
PPD BC#: 58004-01
Date Issued: February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budget as of Project Addendum Modification #1 Cumulative
Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1_
Department/Activity Unit Type Unit Cost NA Total Hours NA # of Units
NA Budget NA Total Hours NA # of Units NA Budget NA Total Hours NA # of Units NA Budget NA Justification
Unblinded Medical Monitor ** ** ** ** ** ** ** ** New
activity added to capture labor associated with an Unblinded Medical Monitor.
PVGProtocol Amendment 1 ** ** ** New activity added to capture the additional
labor needed for Protocol Amendment 1.
Subtotal ** ** ** **
Biostats Team
Management Activity increased due to the seven (7) month timeline extension.
Mapping Raw Data to Study Data Tabulation Model (SDTM) New activity added to
capture labor associated with the mapping of raw data to the Study Data Tabulation Module (SDTM).
BiostatisticsProtocol Amendment 1 ** ** ** ** ** New
activity added to capture the additional labor needed for Protocol Amendment 1.
Subtotal ** ** ** ** **
Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Review CRF ** ** ** ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved.
Medical WritingProtocol Amendment 1 ** ** ** ** ** ** New activity added to capture the additional labor needed for Protocol Amendment 1.
Subtotal ** ** ** **
Information Governance & ComplianceCountry File Set-up
Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Information Governance & ComplianceCountry File
Archiving and Transfer ** ** ** ** ** Activity decreased as unit is no longer projected to be achieved, due to the study leaving Canada.
Clinical Supplies
OAProject Agreements *. * *. ** » Activity decreased as unit is no longer projected to be achieved.
Clinical Supplies QAProject Support **
** *. Activity decreased as unit is no longer projected to be achieved.
Subtotal ** ** ** **
Registration of Clinical TrialsMaintenance Activity increased due to the seven (7) month timeline extension.
** ** ** ** ** **
PharmacokineticsProtocol Amendment 1 New activity added to capture the
additional labor needed for Protocol Amendment 1.
Subtotal
Inflation: Added a
line item inflation adjustment to capture inflationary increases associated with the seven (7) month increase to the study duration.
Timeline Extension
Services Discount (CM1): ** ** ** ** PPD is providing a one-time discount associated with services performed in regards to the seven (7) month timeline extension.
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budget as of Project Addendum Modification #1 Cumulative
Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1
Department/Activity Unit Type Unit Cost NA Total Hours NA # of Units
NA Budget NA Total Hours NA # of Units NA Budget NA Total Hours NA # of Units NA Budget NA Justification
Pass Through Costs
Central Laboratory Fees ** ** ** ** ** ** ** ** ** ** ** Activity increased due to the seven (7) month timeline extension.
Investigator Fees ** ** ** ** ** ** ** ** ** ** ** Activity increased due to Protocol Amendment
Site Closeout VisitsTravel ** ** ** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor requested an additional site.
Site Initiation VisitsTravel ** ** ** ** ** ** ** ** ** ** ** Activity increased due to additional unit needed, as sponsor requested an additional site.
Central ReaderHVPG ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the costs projected through the duration of the study.
Central ReaderLiver Biopsy ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the costs projected through the duration of the study.
Data Safety Monitoring Board Member Honoraria ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the costs needed to include payments for three (3) members, which
will cover the contracted caps for each member.
Site Evaluation VisitsHVPGCentral Reader ** ** ** ** ** ** ** ** ** ** ** New activity added to capture
the costs needed to do a site evaluation visit for HVPG Central Reader.
Site Closeout VisitsHVPGCentral Reader ** ** ** ** ** ** ** ** ** ** ** New
activity added to capture the costs needed to do a site closeout visit for HVPG Central Reader.
Site Closeout VisitsLiver BiopsyCentral Reader ** ** **
** ** ** ** ** ** ** ** New activity added to capture the costs needed to do a site closeout visit for Liver Biopsy Central Reader.
Intenm Monitoring Visits-
HVPGCentral Reader ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the costs needed to do a interim monitoring visit for HVPG Central Reader.
Interim Monitoring VisitsLiver BiopsyCentral Reader ** ** ** ** ** ** ** ** ** ** ** New activity added to capture the costs needed to do a interim
monitoring visit for Liver Biopsy Central Reader.
Investigator Meeting TravelClinical Supplies Project Manager ** ** ** ** ** ** ** ** ** ** ** New activity
added to capture the cost for Clinical Supplies Project Manager to attend the Investigator Meeting.
Total Pass Throughs ** ** ** $7,554,800.28
Total Study Costs ** $7,771,786.33
Subtotals and Totals included in the Cumulative and Prior
sections are for reference to the budget grid only and do no represent totaling of the numbers included in this document. The Discrete Subtotals and Totals are representative of the numbers in this document.
PPD Proprietary and Confidential
PPD BC#: 58D04-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION
Modification #1
Cumulative Study Budget as of Project Addendum Modification #1 Cumulative
Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1
Department/Activity Unit Type Unit Cost EMEA Total Hours EMEA # of
Units EMEA Budget EMEA Total Hours EMEA # of Units EMEA Budget EMEA Total Hours EMEA # of Units EMEA Budget EMEA Justification
Pharmacovigilance
Pharmacovigilance Team Management ** ** *. ** ** ** ** M Activity increased due to the seven (7) month timeline extension.
_Subtotal ** ** ** ** ** **
Total Direct Costs ** ** ** ** ** **
Inflation: Added a line item inflation adjustment to capture inflationary increases associated with the seven (7) month increase to the study duration.
Total Discounted Direct Costs ** ** ** ** ** **
Pass Through Costs
Central Labs Quote EMEA ** ** M ** m ** m Activity increased due to the seven (7) month timeline extension.
Total Pass Throughs ** ** ** ** ** **
Total Study Costs ** ** ** ** ** **
Subtotals and Totals included in the Cumulative an
d Prior sections are for reference to the
budget grid only and do not represent totaling of the numbers included in (his document. The Discrete Subtotals an
d Totals are representative of the numbers in this d
ocument.
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Exhibit C
Revised Central Labs Budget
The Revised Central Labs Budget follows this cover page
Page 13 of 31
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Lab, LLC Budget Estimate
PPD Central Labs
09-Jul-2015
Galectin Therapeutics, Inc.
GT-025
BC: 58004-01 Sc2 M1
Central Lab BC: 58004-02 mod #1
Budget Summary Total Charge (USD)
GT-025
Laboratory Testing **
Sample Management **
Kits and Supplies **
Clinical Trial Services Fees **
Direct Costs Estimate: **
_Logistics (Pass-Through) Estimate: **
Total Estimate: **
Original Contract (Rev 2)
Budget Summary Total Charge {USD) Differences
GT-025
Laboratory Testing ** **
Sample Management ** **
Kits and Supplies ** **
Clinical Trial Services Fees ** **
Direct Costs Estimate: ** **
Logistics (Pass-Through) Estimate: ** **
Total Estimate: ** **
Regional Budget Summary GT-025 NA & LA Region EMEA Region
AsiaPac Region China
Laboratory Testing ** ** ** **
Sample Management ** **
** **
Kits and Supplies ** ** ** **
Clinical Trial Services Fees ** ** ** **
Regional Direct Costs Estimate: ** ** ** **
Regional Logistics (Pass-Through)
Estimate: ** ** ** **
Regional Total Estimate: ** ** ** **
Countries Sites
Screened Subjects Enrolled Subjects Completed Subjects %
United States ** ** ** ** **
Canada ** ** ** ** **
North America ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Labs, LLC Budget Estimate
# Patients: 260 260 26 156 156 156 156 156 156 156 156 156 156 156 156 156 156 16 0%
SV1 SV2
5V3 Ml NDV1 HDV2 Visit 2 V3 V4 NDV3 V7 VII V13 V20 V26 14-26 Day After 14 Days After NA&
Shipping Screen in g Random nation
LeOo ret -Dry Test i ng As sumptions Frequency ipment IWeek Screening Screening ^elM) Week 13 Week 51 Week 53-55 Week 57
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
Sample Management |B| SV1 SV2 SV3 VI m NDV2 V>sit2 V, V4 N0V3 V7 v V20 V26 14-28 Dtiy After 14 Days After Toh NA&
?S3 Final Dots LATAM
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
**
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
**
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Labs, LLC Budget Estimate
PPD
Estimate Subjects: US EU
M0D#1
NA & LATAM EMEA region
fx rate=EUR/USD 1.41 14
Laboratory Testing Assumptions UOM NAM A Unit
Charge (USD) Total Charge (USD) EU Unit Charge (Euro) No. Units Total Charge (EUR) Total Charge (USD)
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
Sample Management Assumptions UOM NA & LA Unit Charge
(USD) Total Charge (USD) EU Unit Charge (Euro) No. Units Total Charge (EUR) Total Charge (USD)
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
NA & LATAM region
fx rate=USD/EUR 0.7944 EMEA region
fx rate=EUR/USD 1.4144
Previous Total Charge (USD) Explanation Difference Previous Total
Charge (USD) Explanation Difference
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
Previous Total Charge (USD) Explanation Difference Previous Total Charge
(USD) Explanation Difference
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
PPD Proprietary and Confidentia
PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Labs, LLC Budget Estimate
PPD
Estimate Subjects:
Kits and Supplies Assumptions UOM NA & LA Unit Charge (USD) No. Units Total Charge (USD) EU Unit Charge (Euro) No. Units Total Charge (EUR) Total Charge (USD) Previous
Total Charge (USD) Explanation Difference Previous Total Charge (USD) Explanation Difference
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** **
**
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** **
** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** **
Clinical Trial Services Fees Assumptions UOM NA & LA Unit Charge (USD) No. Units Total Charge (USD) EU Unit Charge (Euro) NO. Units Total Charge (EUR) Total Charge (USD)
Previous Total Charge (USD) Explanation Difference Previous Total Charge (USD) Explanation Difference
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** **
**
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** **
** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** **
** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Labs, LLC Budget Estimate Exchange Rates: Global Logistics (Pass-Through}
Outbound, supplies to sites Inbound, Ambient/Refrig ., sites to PPD Inbound, Frozen, sites to PPD Total Charge
Country Sites Unit Type Courier Unit Cost (Euro) Unit Cost (USD) # of Units Sub-total Courier Unit Cost (Euro) Unit Cost (USD) #of Units Sub-total Courier Unit Cost (Euro) Unit
Cost (USD) # of Unite Sub-total Dry ice and shippers (USD) ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** * ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** Referral lab courier costs Frequency Courier Unit Type Unit
Cost (Euro) Unit Cost (USD) # of Units Su b-total Comments Total Charge (USD) TOTAL PASS THROUGH COSTS TOTAL PASS THROUGH COSTS NA/LA region (USD) MEA gion USD) AsiaPac region (USD) China (USD) Total Differences TOTAL PASS THROUGH COSTS NA/LA region
(USD) $31,287.91 EMEA region (USD) $0.00 AsiaPac region (USD) $0.00 China (USD) $0.00 $31,287.91
* Transportation costs do not include Saturday delivery charges,
taxes, tariffs, duties and fuel surcharge. This will be invoiced at the prevailing rate.
* | Transportation fees are estimates only and based on primary cities. |
* | Client will be invoiced based on actual fees incurred. |
* Laboratory kits may accommodate more than one patient visit/per inbound shipping box. For purposes of the estimate, 1 visit per inbound box
has been assumed as average.
* Drive-away and trans-shipment to international port of departure may apply. Applicable customs fees charged as pass through cost.
* | Inbound transport costs are based on Weekday priority overnight shipments. |
* Outbound kits have standard transit time of 2-5 days. Overnight priority shipping provided with sponsor approval at additional shipping cost. PPD Proprietary and Confidential PPD BC#: 58004-01 Date Issued: 17 February 2016
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPDs Central Labs, LLC Budget Estimate Terms and Conditions Study sst up will commence upon
written acceptance of Contract and Central Laboratory Specifications (CLS). The costs contained within this Proposal are valid for ** from date of proposal. The prices contained within this Proposal are estimates based upon information provided by
Sponsor. Cost will be revised if the Sponsor provides an amended protocol or updated information. *** no charge, regardless of number of users. All protocol materials will be archived for ** from the end of PPD involvement. Requests for protocol
materials will be shipped at the expense of the Sponsor/CRO. *PPD Global Central Labs requires ** from signed CLS for study initiation Study initiation is defined as the first Investigational site to receive specimen collection kits. Sponsor
requested changes ** will result in additional charges to be determined based upon the complexity of the revisions. *PPD Global Central Labs has one global database that supports all regions within the study. Global set-up fees will be invoiced upon
project
initiation once database set-up activities are complete. TRAINING/TRAVEL If requested to attend a Kick off meeting or Investigator meeting, ** Central Labs
presenter at one meeting including preparation, excluding travel expenses billed as pass through. This cost assumes a one day meeting with one day for travel. **. Sponsor request of technical attendees will be charged additional fees of Attendance
at the investigator meeting via WebEx will be charged **, *Site training via conference call for protocol specific laboratory procedures is available at sponsors request. This will be invoiced at **. On site training visits to outline
protocol specific laboratory procedures at the sponsors request, will be invoiced at a rate of **. TRANSPORTATION MODIFICATIONS Any services requested by Sponsor (or sites) and not included in this cost estimate will be charged separately.
Services rendered will be invoiced as performed and a Contract Modification will be issued. Out of protocol testing will be invoiced per the unit price with an additional ** Project Management fee, per request. Additional charges will apply
for any off-cycle or expedited testing. Specimens requiring off-hour technician/processing time, will be invoiced with an added service charge of ** Any sample that is UTP (Unable To Perform) will be charged a Sample Handling fee. A sample
destruction fee will be invoiced for any sample that is required to be destroyed. This fee will be charged per sample destroyed. Expedited shipping fees will be applied at ** with less then notice, plus shipping costs. Additional label sets provided
at an additional fee of **. Additional requisition forms provided at an additional fee of*, Additional collection flow charts (CFC) provided at an additional fee of ** *Set up of additional sites will incur additional site initiation fees and other
applicable charges. Database modifications will be invoiced at ** Non-Standard Services for Data Management and Custom programming will be supplied upon request and billed at a programming rate of ** for services included but not limited to: a.
Custom data file formats b. Custom data management reports c. Data reconciliation requirements Returned kit fee of ** (break-down and disposal of kit contents) plus return shipping charges. Hard copy reports will be invoiced at **. Translation costs
reflect the average cost to translate a typical manual Translation costs for other documents besides the manual, will be charged ** Lab Manuals will be supplied to all sites upon initiation as part of the study set-up. Amended or revised manuals
will be supplied at ** If adjustments to kits are required, the kit tier may be revised and billed at the following rates: This budget for centrai laboratory services is based upon protocol requirements provided at the time of the RFP and is an
estimate only. PPD Central Labs will invoice Sponsor for actual services rendered and testing performed. Invoices may, therefore, differ from the Budget due to differences in actual services rendered versus those contained within this Budget. PPD
Proprietary and Confidential PPDBC#: 5S004-Q1 Date Issued: 17 February 2016 to the omitted portions. Kit Tier NA & LATAM EMEA AsiaPac ** ** ** ** ** ** ** ** ** ** **
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Exhibit D
Revised Study Budget
The Revised Study Budget follows this cover page
Page 20 of 31
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Incremental Budget as of Project Addendum Modification #1 Cumulative Study Budget as of Project Addendum Modification #1 Budget
Budget Budget Budget Budget Budget Department/Activity Total Budget Total Budget Total Budget NA EMEA NA EMEA NA EMEA Project Management ** ** ** ** ** ** ** ** ** Study Start-Up ** ** ** ** ** ** ** ** **
Clinical Management ** ** ** ** ** ** ** ** ** Global Clinical Supplies ** ** ** ** ** ** ** ** **
IVRS ** ** ** ** ** ** ** ** ** Data Management ** ** ** ** ** ** ** ** ** Pharmacovigilance ** ** ** ** ** ** ** ** ** Biostatistics ** ** ** ** ** ** ** ** ** Medical Writing **
** ** ** ** ** ** ** ** Quality Assurance ** ** ** ** ** ** ** ** ** Regulatory Affairs ** ** ** ** ** ** ** ** **
Clinical Pharmacology (PK) ** ** ** ** ** ** **
** ** Electronic Data Capture ** ** ** ** ** ** ** ** ** TOTAL DIRECT COSTS ** ** ** ** ** ** ** ** ** Consulting Services Discount: ** ** ** ** ** ** ** ** **
**
** ** ** ** ** ** ** ** **
** ** ** ** ** ** ** ** ** ** TOTAL DISCOUNTED DIRECT COSTS ** ** ** ** ** ** ** ** ** TOTAL PASS THROUGH COSTS ** ** ** ** ** ** ** **
**
TOTAL STUDY COSTS $22,352,835.61 $393,855.36 $22,746,690.97 $14,581,069.28 $360,734.88 $14,941,804.16 $7,771,766.33 $33,120.47 $7,804,886.80
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Project Management
GPD Consulting protocol ** ** ** ** ** ** ** ** ** Protocol Review protocol
** ** ** ** ** ** ** ** ** Review Data Validation Manual protocol ** ** ** ** ** ** ** ** ** Review CRF protocol ** ** ** ** ** ** ** ** ** Prepare CRF Completion Guidelines case book ** ** ** ** ** ** ** ** ** Project Familiarization &
Initial Team Training protocol ** ** ** ** ** ** ** ** ** Develop Country Budget and Payment Schedule Template country ** ** ** ** ** ** ** ** ** ICF Local CustomizationReview and Approve country ** ** ** ** ** ** ** ** ** ICF Local
CustomizationReview and ApproveAmendments country ** ** ** ** ** ** ** ** ** Review SAP (PPD or Client) plan ** ** ** ** ** ** ** ** ** Identify Third Party Vendors vendor ** ** ** ** ** ** ** ** ** Vendor ManagementPPD Managed
Vendors vendor month ** ** ** ** ** ** ** ** ** Develop and Negotiate Site Contract Language, Budget and Payment site ** ** ** ** ** ** ** ** ** Schedule Investigator Grant Payment Administration payment ** ** ** ** ** ** ** ** ** IND Safety Reports
report ** ** ** ** ** ** ** ** ** Clinical Site Audits audit ** ** ** ** ** ** ** ** ** Final Analysis Review report ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Investigator Meeting attendee ** ** ** **
** ** ** ** ** Face to Face Client Meetings meeting ** ** ** ** ** ** ** ** ** Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal Team Meetings and Ongoing Training meeting ** ** ** ** ** ** ** ** ** Project
ManagementStart-up month ** ** ** ** ** ** ** ** ** Project ManagementEnrollment month ** ** ** ** ** ** ** ** ** Project ManagementTreatment month ** ** ** ** ** ** ** ** ** Project ManagementClose Out month ** ** ** ** **
** ** ** ** Study Newsletters newsletter ** ** ** ** ** ** ** ** ** Project ManagementProtocol Amendment 1 amendment ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Study Start-Up
Project Familiarization & Initial Team Training protocol ** ** ** **
** ** ** ** ** CTMS Central Setup protocol ** ** ** ** ** ** ** ** ** CTMS Country Setup country ** ** ** ** ** ** ** ** ** CTMS Site Implementation site ** ** ** ** ** ** ** ** ** ICF Local Customization country ** ** ** ** ** ** ** ** **
Management of Translation of Protocol, Investigator Brochure, ICF & translation ** ** ** ** ** ** ** ** ** Technical Documents Review of Translation of ICF translation ** ** ** ** ** ** ** ** ** Clinical Site Identification site ** ** ** **
** ** ** ** ** Pre-Study Visit Waiver PSV waiver ** ** ** ** ** ** ** ** ** Site Evaluation VisitsPrep/Admin/Follow-up visit ** ** ** ** ** ** ** ** ** Site Evaluation VisitsTime on Site visit ** ** ** ** ** ** ** ** ** Site Evaluation
VisitsTravel visit ** ** ** ** ** ** ** ** ** Collect and Verify Regulatory Docs site ** ** ** ** ** ** ** ** ** Local Ethics Submissions site ** ** ** ** ** ** ** ** ** Central Ethics SubmissionsCountry Specific country ** ** ** ** **
** ** ** ** Develop and Negotiate Site Contract Language site ** ** ** ** ** ** ** ** ** Investigator Grant Payment Negotiation site ** ** ** ** ** ** ** ** ** Develop Site Budget and Payment Schedule study ** ** ** ** ** ** ** ** ** Legal Template
Process Negotiation Activities study ** ** ** ** ** ** ** ** ** Negotiate CDA site ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal Team Meetings and Ongoing Training meeting ** ** ** ** ** ** ** ** ** Site Intelligence and Activation
Management month ** ** ** ** ** ** ** ** ** Hepatic Venous Pressure Gradient (HVPG) Vendor Site Evaluation Visit visit ** ** ** ** ** ** ** ** ** Prep/Follow-up HVPG Vendor Site Evaluation VisitTime On Site visit ** ** ** ** ** ** ** ** **
HVPG Vendor Site Evaluation VisitTravel visit ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Clinical Management
Prepare Monitoring Plan protocol ** ** ** ** ** ** ** ** ** Review Protocol protocol ** ** ** ** ** ** ** ** ** Review CRF protocol ** ** ** ** ** ** ** ** ** Prepare CRF
Completion Guidelines case book ** ** ** ** ** ** ** ** ** Project Familiarization & Initial Team Training protocol ** ** ** ** ** ** ** ** ** Unblinded Project Familiarization & Initial Team Training protocol ** ** ** ** ** ** **
** ** Develop Country Budget and Payment Schedule Template country ** ** ** ** ** ** ** ** ** Design Master ICF protocol ** ** ** ** ** ** ** ** ** ICF Local CustomizationAmendments country ** ** ** ** ** ** ** ** ** Review of Site-Specific
ICF Post ECAmendments site ** ** ** ** ** ** ** ** ** IRB/EC Annual Renewals site ** ** ** ** ** ** ** ** ** Collect and Verify Reg DocsAmendments site ** ** ** ** ** ** ** ** ** Investigator BrochureAnnual Update to Ethics
Committee site year ** ** ** ** ** ** ** ** ** AmendmentsManagement of Translation of Protocol, Investigator translation ** ** ** ** ** ** ** ** ** Brochure, ICF & Technical Documents AmendmentsReview of Translation of ICF
translation ** ** ** ** ** ** ** ** ** Clinical Site Identification site ** ** ** ** ** ** ** ** ** Site Evaluation VisitsPrep/Admin/Follow-up visit ** ** ** ** ** ** ** ** ** Site Initiation VisitsPrep/Admin/Follow-up visit ** ** ** **
** ** ** ** ** Site Initiation VisitsTime on Site visit ** ** ** ** ** ** ** ** ** Site Initiation VisitsTravel visit ** ** ** ** ** ** ** ** ** Interim Monitoring VisitsPrep/Admin/Follow-Up visit ** ** ** ** ** ** ** ** ** Interim
Monitoring VisitsTime on Site visit ** ** ** ** ** ** ** ** ** Interim Monitoring VisitsTravel visit ** ** ** ** ** ** ** ** ** Site Management site month ** ** ** ** ** ** ** ** ** Unblinded Site Management site month ** ** ** ** ** **
** ** ** Annual Investigator File Audits file audit ** ** ** ** ** ** ** ** ** Vendor ManagementPPD Managed Vendors vendor month ** ** ** ** ** ** ** ** ** Develop and Negotiate Site Contract Language, Budget and Payment site ** ** ** ** ** **
** ** ** Schedule Investigator Payment Administration payment ** ** ** ** ** ** ** ** ** Management of Non-Drug Trial Supplies shipment ** ** ** ** ** ** ** ** ** Clinical Site Audits audit ** ** ** ** ** ** ** ** ** In-house CRF Review CRF page **
** ** ** ** ** ** ** ** Query Resolution query ** ** ** ** ** ** ** ** ** Unblinded Drug Accountability VisitsPrep/Admin/Follow-up visit ** ** ** ** ** ** ** ** ** Unblinded Drug Accountability VisitsTime on Site visit ** ** ** ** ** **
** ** ** Unblinded Drug Accountability VisitsTravel visit ** ** ** ** ** ** ** ** ** Site Closeout VisitsPrep/Admin/Follow-up visit ** ** ** ** ** ** ** ** ** Site Closeout VisitsTime on Site visit ** ** ** ** ** ** ** ** ** Site
Closeout VisitsTravel visit ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Unblinded Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Investigator Meeting attendee ** ** ** ** ** ** **
** ** Unblinded Investigator Meeting attendee ** ** ** ** ** ** ** ** ** Face to Face Client Meetings meeting ** ** ** ** ** ** ** ** **
PPD Proprietary and
Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal Team Meetings and Ongoing Training meeting ** ** ** ** ** ** ** ** ** Unblinded Internal Team Meetings and
Ongoing Training meeting ** ** ** ** ** ** ** ** ** CRA Team Meetings meeting ** ** ** ** ** ** ** ** ** Unblinded CRA Team Meetings meeting ** ** ** ** ** ** ** ** ** Protocol Inquiry Forms Management PIF ** ** ** ** ** ** ** ** ** Clinical Team
Management month ** ** ** ** ** ** ** ** ** Unblinded Clinical Team Management month ** ** ** ** ** ** ** ** ** Study Newsletters newsletter ** ** ** ** ** ** ** ** ** Clinical ManagementProtocol Amendment 1 amendment ** ** ** ** ** ** ** **
** HVPG Vendor Interim Monitoring VisitsPrep/Follow-Up visit ** ** ** ** ** ** ** ** ** HVPG Vendor Interim Monitoring VisitsTime On Site visit ** ** ** ** ** ** ** ** ** HVPG Vendor Interim Monitoring VisitsTravel visit ** ** **
** ** ** ** ** ** HVPG Vendor Site Closeout VisitPrep/Follow-Up visit ** ** ** ** ** ** ** ** ** HVPG Vendor Site Closeout VisitTime On Site visit ** ** ** ** ** ** ** ** ** HVPG Vendor Site Closeout VisitTravel visit ** ** ** **
** ** ** ** ** Liver Biopsy Vendor Interim Monitoring VisitsPrep/Follow-Up visit ** ** ** ** ** ** ** ** ** Liver Biopsy Vendor Interim Monitoring VisitsTime On Site visit ** ** ** ** ** ** ** ** ** Liver Biopsy Vendor Interim Monitoring
VisitsTravel visit ** ** ** ** ** ** ** ** ** Liver Biopsy Vendor Site Closeout VisitsPrep/Follow-Up visit ** ** ** ** ** ** ** ** ** Liver Biopsy Vendor Site Closeout VisitsTime On Site visit ** ** ** ** ** ** ** ** ** Liver
Biopsy Vendor Site Closeout VisitsTravel visit ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Global Clinical Supplies
Project Setup protocol ** ** ** ** ** ** ** ** ** Identify, Select and Negotiate Contracts with Clinical Supply Vendors vendor ** ** ** ** ** ** ** ** ** Label Text Development
label ** ** ** ** ** ** ** ** ** Label Text Translation Coordination country ** ** ** ** ** ** ** ** ** Clinical Supply Forecasting forecast ** ** ** ** ** ** ** ** ** Monitor/Track Study Progress, Inventory Levels and Communication with month ** **
** ** ** ** ** ** ** Team/Sponsor randomized Final Drug Accountability and Destruction ** ** ** ** ** ** ** ** ** patient Kick Off Meeting meeting ** ** ** ** ** ** ** ** ** Depot Management depot month ** ** ** ** ** ** ** ** ** Distribution
Management shipment ** ** ** ** ** ** ** ** ** Investigators Meeting meeting ** ** ** ** ** ** ** ** ** Global Clinical SuppliesProtocol Amendment 1 amendment ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
IVRS
Base System Set-up protocol ** ** ** ** ** ** ** ** ** Code Break Module protocol ** **
** ** ** ** ** ** ** Confirm Receipt Module protocol ** ** ** ** ** ** ** ** ** Randomization Module protocol ** ** ** ** ** ** ** ** ** Screening Module protocol ** ** ** ** ** ** ** ** ** Subject Status Change Module protocol ** ** ** ** ** ** **
** ** Supplies Ordering ManagementSite protocol ** ** ** ** ** ** ** ** ** Telephone Line Setup protocol ** ** ** ** ** ** ** ** ** User Acceptance Testing protocol ** ** ** ** ** ** ** ** ** Visit Tracking Module protocol ** ** ** ** ** ** **
** ** Web Technical Setup protocol ** ** ** ** ** ** ** ** ** Project Closeout protocol ** ** ** ** ** ** ** ** ** User Information/Security Management (PINs) site user ** ** ** ** ** ** ** ** ** Site Based System Support site month ** ** ** ** **
** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget
NA NA EMEA EMEA EMEA
System SupportBase month ** ** ** ** ** ** ** ** **
User Guide Creation user guide ** ** ** ** ** ** ** ** **
Data InterfacesRepeat repeat
interface ** ** ** ** ** ** ** ** **
Data TransfersRepeat repeat transfer ** ** ** ** ** ** ** ** **
Data TransfersUnique unique transfer ** ** ** ** ** ** ** ** **
system custom
System Custom Coding ** ** ** ** ** ** ** ** **
coding
Standard Reports Report ** ** ** ** ** ** ** ** **
Configurable Reports Report ** ** ** ** **
** ** ** **
Custom Reports Report ** ** ** ** ** ** ** ** **
Kick-off Meeting
with Client meeting ** ** ** ** ** ** ** ** **
Investigator Meeting attendee ** ** ** ** ** ** ** ** **
Client Teleconferences teleconference ** ** ** ** ** ** ** ** **
Internal Project Team
Meetings/Ongoing Training meeting ** ** ** ** ** ** ** ** **
IVRS Team Management month ** ** ** ** ** ** ** ** **
Investigational Product (IP) Accountability Module protocol ** ** ** ** ** ** ** ** **
Subtotal ** ** ** ** **
Data Management
Database Design/Build/Validation unique page ** ** ** ** ** ** ** ** **
Coding Set-up study **
** ** ** ** ** ** ** **
Mock Screen Layout Design unique page ** ** ** ** ** ** ** ** **
Project Start-Up protocol ** ** ** ** ** ** ** ** **
Transfer ActivitiesSet-Up protocol
** ** ** ** ** ** ** ** **
Data Validation System DesignDVM DVM ** ** ** ** ** ** ** ** **
Data Validation System Designedits edit check ** ** ** ** ** ** ** ** **
Data Validation
System Designlistings output ** ** ** ** ** ** ** ** **
Data Validation System Developmentedits edit check ** ** ** ** ** ** ** ** **
Data Validation System Developmentlistings output ** ** ** ** ** ** ** ** **
Data
Validation page ** ** ** ** ** ** ** ** **
Data Validation System Validationedits edit check ** ** ** ** ** ** ** ** **
Data Validation System Validationlistings output ** ** ** ** ** ** ** ** **
Project
Tracking month ** ** ** ** ** ** ** ** **
Medical Terminology Coding verbatim term ** ** ** ** ** ** ** ** **
Data Imports import ** ** ** ** ** ** ** ** **
Data ImportsImport Sources import source
** ** ** ** ** ** ** ** **
Data Reconciliation import ** ** ** ** ** ** ** ** **
Transfer ActivitiesExports export ** ** ** ** ** ** ** ** **
Transfer
ActivitiesUnique Page unique page ** ** ** ** ** ** ** ** **
Query query ** ** ** ** ** ** ** ** **
SAE SAE ** ** ** ** ** ** ** ** **
Discrepancies discrepancy ** ** ** ** ** ** ** ** **
Archive Study study ** ** ** ** ** ** ** ** **
finalized
Finalized Database ** ** ** ** ** ** ** ** **
database
Data Review Meetings meeting ** ** ** ** ** ** ** ** **
Kick-off Meeting with Client meeting
** ** ** ** ** ** ** ** **
Investigator Meeting attendee ** ** ** ** ** ** ** ** **
Client Teleconferences teleconference ** ** ** ** ** ** ** ** **
Internal Team Meetings
meeting ** ** ** ** ** ** ** ** **
Quality Management year ** ** ** ** ** ** ** ** **
DM Project Management month ** ** ** ** ** ** ** ** **
Data ManagementProtocol Amendment
1 amendment ** ** ** ** ** ** ** ** **
Subtotal ** ** ** ** **
Pharmacovigilance
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Pharmacovigilance Set-up protocol ** ** ** ** ** ** ** ** ** Regulatory Reporting Set-Up protocol ** ** ** ** ** ** ** ** ** Data Safety Monitoring Board Set-up protocol ** ** **
** ** ** ** ** ** RevisedData Safety Monitoring Board Set-up protocol ** ** ** ** ** ** ** ** ** Safety DatabaseSet-up protocol ** ** ** ** ** ** ** ** ** Analysis of Similar Events analysis ** ** ** ** ** ** ** ** ** Development Safety
Update Report (DSUR) Preparation report ** ** ** ** ** ** ** ** ** Event Reconciliation SAE ** ** ** ** ** ** ** ** ** Expedited Report Submissions submission ** ** ** ** ** ** ** ** ** Medical Protocol Inquiries inquiry ** ** ** ** ** ** ** ** **
Protocol Deviation Reviews/Determine Evaluability Sets month ** ** ** ** ** ** ** ** ** Medical Review of Alert Labs protocol ** ** ** ** ** ** ** ** ** Medical Review of Coding review ** ** ** ** ** ** ** ** ** Medical Review of Safety Listings
review ** ** ** ** ** ** ** ** ** Periodic Safety Report Preparation report ** ** ** ** ** ** ** ** ** Physician Assessment Diagnostic Forms PADF ** ** ** ** ** ** ** ** ** SAE/Event Processing SAE ** ** ** ** ** ** ** ** ** Senior Medical Officer
for CanadaStart-up protocol ** ** ** ** ** ** ** ** ** Senior Medical Officer for CanadaMonthly Maintenance month ** ** ** ** ** ** ** ** ** Senior Medical Officer Review of Canadian CTA CTA review ** ** ** ** ** ** ** ** **
CTA amendment
Senior Medical Officer Review of Canadian CTA Amendment ** ** ** ** ** ** ** **
** review
Pharmacovigilance Close-out protocol ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Investigator Meeting
attendee ** ** ** ** ** ** ** ** ** Data Safety Monitoring Board Face-to-Face Meeting meeting ** ** ** ** ** ** ** ** ** RevisedData Safety Monitoring Board Face to Face Meeting meeting ** ** ** ** ** ** ** ** ** Data Safety Monitoring Board
Teleconference Meeting meeting ** ** ** ** ** ** ** ** ** RevisedData Safety Monitoring Board Teleconference Meeting meeting ** ** ** ** ** ** ** ** ** Pharmacovigilance Team Management month ** ** ** ** ** ** ** ** ** Data Safety Monitoring
Board Project Management month ** ** ** ** ** ** ** ** ** Safety DatabaseMonthly Management month ** ** ** ** ** ** ** ** ** Unblinded Medical Monitor month ** ** ** ** ** ** ** ** ** PVGProtocol Amendment 1 amendment ** ** ** ** ** **
** ** ** Subtotal ** ** ** ** **
Biostatistics
DSMB meeting meeting ** ** **
** ** ** ** ** ** Data Validation Manual protocol ** ** ** ** ** ** ** ** ** Design/Review Protocol protocol ** ** ** ** ** ** ** ** ** Initial Project Training protocol ** ** ** ** ** ** ** ** ** Produce/Review Statistical Analysis Plan (SAP) plan
** ** ** ** ** ** ** ** ** Randomization Schedule protocol ** ** ** ** ** ** ** ** ** Review CRF protocol ** ** ** ** ** ** ** ** ** Project Setup protocol ** ** ** ** ** ** ** ** ** DSMBProduce/Review Statistical Analysis Plan (SAP) plan **
** ** ** ** ** ** ** ** DSMB AnalysisDatabase analysis dataset ** ** ** ** ** ** ** ** ** DSMBTLF Shells shell ** ** ** ** ** ** ** ** ** DSMB AnalysisTables table ** ** ** ** ** ** ** ** ** DSMB AnalysisListings listing **
** ** ** ** ** ** ** ** IND AnalysisDatabase analysis dataset ** ** ** ** ** ** ** ** ** IND AnalysisTables table ** ** ** ** ** ** ** ** ** Full AnalysisDatabase analysis dataset ** ** ** ** ** ** ** ** ** Full AnalysisTLF
Shells shell ** ** ** ** ** ** ** ** ** Full AnalysisTables table ** ** ** ** ** ** ** ** **
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Full AnalysisListings listing ** ** ** ** ** ** ** ** ** Full AnalysisFigures figure ** ** ** ** ** ** ** ** ** Full AnalysisReport report ** ** ** ** ** ** ** **
** Project Archiving study ** ** ** ** ** ** ** ** ** Data Review Meetings meeting ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal
Team Meetings and Ongoing Training meeting ** ** ** ** ** ** ** ** ** Biostats Team Management month ** ** ** ** ** ** ** ** ** Mapping Raw Data to Study Data Tabulation Model (SDTM) mapping ** ** ** ** ** ** ** ** ** BiostatisticsProtocol
Amendment 1 amendment ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Medical Writing
DSUR study ** ** ** ** ** ** ** ** ** Review CRF protocol ** ** ** ** ** ** ** ** ** Project Familiarization & Initial Team Training protocol ** ** ** ** ** ** ** ** **
Prepare SAE Narratives for Final Report narrative ** ** ** ** ** ** ** ** ** Prepare Final Integrated Report report ** ** ** ** ** ** ** ** ** Prepare Mock Final Integrated Report report ** ** ** ** ** ** ** ** ** Prepare Draft 1 Final Integrated
Report report ** ** ** ** ** ** ** ** ** Prepare Final Integrated ReportAppendices appendices set ** ** ** ** ** ** ** ** ** Prepare Final Integrated ReportPublishing publishing ** ** ** ** ** ** ** ** ** Data Review Meetings meeting **
** ** ** ** ** ** ** ** Kick-off Meeting with Client meeting ** ** ** ** ** ** ** ** ** Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal Team Meetings meeting ** ** ** ** ** ** ** ** ** Medical Writing Project Maintenance
month ** ** ** ** ** ** ** ** ** Medical WritingProtocol Amendment 1 month ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Quality Assurance
Clinical QAProject Familiarization & Initial Team Training protocol ** ** ** ** ** ** ** ** ** Clinical QAClinical Investigator Site Audit audit ** ** ** ** **
** ** ** ** Clinical QAProject Support month ** ** ** ** ** ** ** ** ** Information Governance & ComplianceInvestigator Files Set-up site ** ** ** ** ** ** ** ** ** Information Governance & ComplianceInvestigator
File Maintenance site month ** ** ** ** ** ** ** ** ** Information Governance & ComplianceInvestigator Files Archiving and site ** ** ** ** ** ** ** ** ** Transfer
Information Governance & ComplianceUnblinded Investigator Files Set-up site ** ** ** ** ** ** ** ** **
Information Governance & ComplianceUnblinded Investigator File site month ** ** ** ** ** ** ** ** ** Maintenance Information Governance &
ComplianceUnblinded Investigator Files site ** ** ** ** ** ** ** ** ** Archiving and Transfer
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Information Governance & ComplianceCountry File Set-up country ** ** ** ** ** ** ** ** ** Information Governance & ComplianceCountry File Maintenance
month ** ** ** ** ** ** ** ** **
Information Governance & ComplianceCountry File Archiving and Transfer country ** ** ** ** ** ** ** ** **
Information Governance & ComplianceCentral File Set-up protocol ** ** ** ** ** ** ** ** ** Information Governance & ComplianceCentral
File Maintenance month ** ** ** ** ** ** ** ** **
Information Governance & ComplianceCentral File Archiving and Transfer protocol ** ** ** ** ** **
** ** **
Clinical Supplies QAProject Agreements study ** ** ** ** ** ** ** ** ** Clinical Supplies QAProject Support study ** ** ** ** ** ** ** ** **
Subtotal ** ** ** ** **
Regulatory Affairs
Clinical Trial
Application/AuthorizationCountry Specific Submissions country ** ** ** ** ** ** ** ** ** Clinical Trial Application/AuthorizationVariations and Amendments country ** ** ** ** ** ** ** ** ** Clinical Trial
Application/AuthorizationManagement month ** ** ** ** ** ** ** ** ** Clinical Trial Application/AuthorizationAnnual/Progress Reports report ** ** ** ** ** ** ** ** ** Registration of Clinical TrialsInitial protocol ** ** ** ** **
** ** ** ** Registration of Clinical TrialsMaintenance month ** ** ** ** ** ** ** ** ** Regulatory Review of Clinical Trial Labeling protocol ** ** ** ** ** ** ** ** ** Regulatory Compliance Review site ** ** ** ** ** ** ** ** ** Regulatory
Compliance ReviewAmendments site ** ** ** ** ** ** ** ** ** Safety Report Submissions submission ** ** ** ** ** ** ** ** ** Notification of End of Trial (Health Authority) protocol ** ** ** ** ** ** ** ** ** Kick-off Meeting with Client
meeting ** ** ** ** ** ** ** ** ** Client Teleconferences teleconference ** ** ** ** ** ** ** ** ** Internal Team Meetings and Ongoing Training meeting ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Clinical Pharmacology (PK)
Clean and Format Bioanalytical and CRF Data for NONMEM Datasets
-study ** ** ** ** ** ** ** ** ** POP
Project SetupPOP study ** ** ** ** ** ** ** ** ** Produce/PK Input to Population PKPD Analysis PlanPOP plan ** **
** ** ** ** ** ** ** Generation of NONMEM datasetsPOP dataset ** ** ** ** ** ** ** ** ** Generation of PKPD DatasetsNCA analysis dataset ** ** ** ** ** ** ** ** ** Generation of PKPD TLFsNCA PKPD TLF set ** ** ** ** ** ** ** ** **
Population PK Analysis, Covariate Analysis, Model EvaluationPOP analyze ** ** ** ** ** ** ** ** ** Produce Population PKPD Study ReportPOP report ** ** ** ** ** ** ** ** ** PK Project Team MeetingsPOP month ** ** ** ** ** ** ** **
** PharmacokineticsProtocol Amendment 1 amendment ** ** ** ** ** ** ** ** ** Subtotal ** ** ** ** **
Electronic Data Capture
EDC Project Set-up protocol ** ** ** ** ** ** ** ** ** EDC Study Closeout protocol ** ** ** ** ** ** ** ** ** Internal Team Meetings and Ongoing Training meeting ** ** ** ** ** **
** ** ** Subtotal ** ** ** ** **
Total Direct Costs ** ** ** ** **
Consulting
Services Discount: ** **
** ** ** **
** ** **
Total Discounted Direct Costs ** ** $9,084,692.63
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
|
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PROJECT ADDENDUM MODIFICATION Modification #1
Cumulative Study Budget as of Project Addendum Modification #1
Total Hours # of Units Total
Hours Unit Cost # of Units
Department/Activity Unit Type Unit Cost NA Budget NA Budget EMEA Total Budget NA NA EMEA EMEA EMEA
Pass Through Costs
BioA Quote report ** ** ** ** ** ** ** ** ** Central Laboratory Fees
protocol ** ** ** ** ** ** ** ** ** Central Labs Quote EMEA report ** ** ** ** ** ** ** ** ** Clinical Site AuditTravel audit ** ** ** ** ** ** ** ** ** Data Safety Monitoring Board Meetings meeting ** ** ** ** ** ** ** ** ** EDC CD Building
Material site ** ** ** ** ** ** ** ** ** Face to Face Client MeetingsTravel attendee ** ** ** ** ** ** ** ** ** Host Investigator Meeting study ** ** ** ** ** ** ** ** ** Importation costs for Supplies study ** ** ** ** ** ** ** ** ** Interim
Monitoring VisitsTravel visit ** ** ** ** ** ** ** ** ** Investigator Fees patient ** ** ** ** ** ** ** ** ** IRB/EC Fees site ** ** ** ** ** ** ** ** ** IVRCourier Charges for PIN Packets site user ** ** ** ** ** ** ** ** ** translation
per IVRSystem Translations & Voice Recordings ** ** ** ** ** ** ** ** ** language IVRTelephone Line Charges call ** ** ** ** ** ** ** ** ** Kick-off Meeting With ClientTravel attendee ** ** ** ** ** ** ** ** ** Management
of Packaging and Labeling packaging run ** ** ** ** ** ** ** ** ** Medidata Rave Services site month ** ** ** ** ** ** ** ** ** Site Closeout VisitsTravel visit ** ** ** ** ** ** ** ** ** Site Evaluation VisitsTravel visit ** ** ** ** **
** ** ** ** Site Initiation VisitsTravel visit ** ** ** ** ** ** ** ** ** Study Drug Label Text Translations Fees protocol ** ** ** ** ** ** ** ** ** Third Party Depot Costs protocol ** ** ** ** ** ** ** ** ** Translation of various documents
(excluding protocol) document ** ** ** ** ** ** ** ** ** Unblinded Drug Accountability VisitsTravel visit ** ** ** ** ** ** ** ** ** Central ReaderHVPG vendor ** ** ** ** ** ** ** ** ** Central ReaderLiver Biopsy vendor ** ** ** **
** ** ** ** ** Data Safety Monitoring Board Member Honoraria meeting ** ** ** ** ** ** ** ** ** Site Evaluation VisitsHVPGCentral Reader visit ** ** ** ** ** ** ** ** ** Site Closeout VisitsHVPGCentral Reader visit ** ** **
** ** ** ** ** ** Site Closeout VisitsLiver BiopsyCentral Reader visit ** ** ** ** ** ** ** ** ** Interim Monitoring VisitsHVPGCentral Reader visit ** ** ** ** ** ** ** ** ** Interim Monitoring VisitsLiver
BiopsyCentral Reader visit ** ** ** ** ** ** ** ** ** Investigator Meeting TravelClinical Supplies Project Manager meeting ** ** ** ** ** ** ** ** **
Total Pass Throughs ** ** **
Total Study Costs $22,352,835.61 $393,855.36
$22,746,690.97
PPD Proprietary and Confidential
PPD BC#: 58004-01
Date Issued: 17 February 2016
Modification Number: 1
PROJECT ADDENDUM MODIFICATION
Exhibit E
Revised Payment Schedule
The Revised Payment Schedule follows this cover page
Page 30 of 31
** | Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. |
PPD Payment Schedule
Sponsor: Galectin BC Number: 58004-01 Protocol :GT-026
Direct Costs:
Execution of Contract **
Monthly **
Project Management Fee **
** **
Milestones: **
** **
**
**
**
**
** **
**
** **
** **
** **
**
** **
** **
Total Direct Costs **
Indirect Costs: **
** **
Total Clinical Grants **
** **
Total Pass Through Costs **
Project Grand Total 22,746,690.97
** **
** **
* | * ** |
PPD Proprietary and Confidential
PPD BC#: 58004-01 Date Issued: 17 February 2016